These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. New countermeasures considered as drug counterfeiting grows. Schubert C Nat Med; 2008 Jul; 14(7):700. PubMed ID: 18607355 [No Abstract] [Full Text] [Related]
24. [Objectives and organization of the International Conference on Harmonization]. Juillet Y Ann Pharm Fr; 1999 Mar; 57(2):137-42. PubMed ID: 10365469 [TBL] [Abstract][Full Text] [Related]
25. [The new norms decreed by the legislative dirrective 91-93 CCE]. Neri M; Palazzo S Boll Chim Farm; 1998 Feb; 137(2):31-4. PubMed ID: 9595832 [TBL] [Abstract][Full Text] [Related]
26. WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organ Tech Rep Ser; 2003; 917():i-viii, 1-125, back cover. PubMed ID: 15024913 [TBL] [Abstract][Full Text] [Related]
27. Toward more effective drug regulation. Schmidt AM FDA Consum; 1975 Dec-1976 Jan; 9(10):27-9. PubMed ID: 10316532 [No Abstract] [Full Text] [Related]
28. 3. Drug regulations in Switzerland and their application. Hippenmeier F Bull Parenter Drug Assoc; 1974; 28(4):167-73. PubMed ID: 4855448 [No Abstract] [Full Text] [Related]
29. WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organization World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684 [TBL] [Abstract][Full Text] [Related]
30. Global perspective on specifications for biotechnology products--perspective from Japan. Hayakawa T Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678 [No Abstract] [Full Text] [Related]
31. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first report. World Health Organization World Health Organ Tech Rep Ser; 2007; (943):1-156. PubMed ID: 17621973 [TBL] [Abstract][Full Text] [Related]
32. [Doctors as naive (innocent) drug advertisers]. Shoenfeld Y Harefuah; 2008 Feb; 147(2):98-9. PubMed ID: 18357661 [No Abstract] [Full Text] [Related]
33. Ingredients in pharmaceutical preparations: a problem not value. Lubner GC Boll Chim Farm; 2002; 141(5):332. PubMed ID: 12481372 [No Abstract] [Full Text] [Related]
34. WHO expert committee on specifications for pharmaceutical preparations. World Health Organ Tech Rep Ser; 1984; 704():1-54. PubMed ID: 6437087 [No Abstract] [Full Text] [Related]
35. Securing the US pharmaceutical supply. Somberg JC Am J Ther; 2008; 15(3):197. PubMed ID: 18496255 [No Abstract] [Full Text] [Related]
36. Development of specifications for biotechnology products--perspective from Europe. Trouvin JH Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679 [No Abstract] [Full Text] [Related]
37. [Novae and other iniquities in pharmacotherapy]. Offerhaus L Ned Tijdschr Geneeskd; 1984 Jan; 128(1):26-30. PubMed ID: 6694762 [No Abstract] [Full Text] [Related]
38. Spurious drugs. Mittal SB J Indian Med Assoc; 2000 Aug; 98(8):464. PubMed ID: 11294333 [No Abstract] [Full Text] [Related]
39. Rationale drug therapy: reasons for failure and suggestions for its implementation. Mathur GP; Kushwaha KP; Mathur S Indian Pediatr; 1993 Jun; 30(6):815-8. PubMed ID: 7726879 [No Abstract] [Full Text] [Related]
40. A proposed European pharmacopeia monograph for continuous cell lines derived drugs. Dorpema JW Dev Biol Stand; 1989; 70():113-24. PubMed ID: 2759345 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]